Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linafexor - Cascade Pharmaceuticals

Next Previous
Drug Profile

Linafexor - Cascade Pharmaceuticals

Alternative Names: CS-0159

Latest Information Update: 14 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cascade Pharmaceuticals
  • Class Anti-inflammatories; Hepatoprotectants; Ketones; Oxadiazoles; Oxazoles; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Primary biliary cirrhosis
  • Phase II Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 06 May 2026 Shanghai Jiao Tong University School of Medicine plans to initiate a clinical trial for Non-alcoholic-fatty-liver-disease (Combination therapy) (PO) in June 2026 (NCT07570810)
  • 01 Apr 2026 Cascade Pharmaceuticals completes a phase I drug-drug interaction trial (In volunteers) (PO, Tablet) (NCT07429331)
  • 09 Mar 2026 Cascade Pharmaceuticals initiates a phase I drug-drug interaction trial (In volunteers) (PO, Tablet) (NCT07429331)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top